Skip to main content
. 2020 Mar 5;22:29–32. doi: 10.1016/j.ctro.2020.03.002

Table 1.

Patient characteristics.

Patient WHO Tumor de-differentiation DOTATOC/-TATE Activity PRRT (GBq) PRRT Dose (Gy) EBRT Dose (Gy) Reduction in EBRT (Gy) Clinical follow-up Radiological follow-up (MRI) PFS (mo) OS (mo) Follow-up (mo) Progression Death
1 2 3 DOTATOC 6.98 4.0 60.0 0 Loss of vision, pituitary insufficiency PD 26.2 38.2 38.2 Yes Yes
2 1 DOTATOC 7.3 6.6 48.6 7 No complaints SD 111.4 111.4 111.4 No No
3 n/a DOTATOC 7.49 4.0 50.4 4 No changes SD 47.2 47.2 47.2 No Yes
4 1 DOTATOC 7.2 0.2 54.0 0 No changes CR 108.9 108.9 108.9 No No
5 1 DOTATOC 7.6 6.7 54.0 0 No changes SD 107.7 107.7 107.7 No No
6 1 DOTATOC 7.9 22.3 41.8 11 No complaints SD 108.7 108.7 108.7 No No
7 1 2 DOTATATE 7.9 30.7 60.0 0 Hemiparesis right PD (03/17), then SD 75.9 105.9 105.9 Yes No
8 2 3 DOTATATE 7.2 7.2 40.0 0 Multiple resections (WHO III), epilepsy PD 13.8 45.6 45.6 Yes Yes
9 n/a n/a DOTATATE 7.3 16.6 54.0 0 Parkinsońs disease SD 104.0 104.0 104 No No
10 1 DOTATATE 7.4 8.2 52.2 6 No changes SD 78.2 78.2 78.2 No No

mo = months; n/a = not available.